Table 1.
Clinical and demographic characteristics
| Subject ID | Age, yr | Sex | Disease Duration, yr | Affected Side (R/l) | PD Medications (Type, Dose) | UPDRS III Off | UPDRS III On |
|---|---|---|---|---|---|---|---|
| p01* | 75 | M | 4 | Pram (0.5 mg), CD-LD (25/100 mg) | 17 | ||
| p02 | 57 | M | 2.5 | R | Pram (3 mg) | 37 | 23 |
| p03 | 62 | M | 4 | R | Pram (4.5 mg), Rasagiline (1 mg) | 22 | 21 |
| p04 | 70 | M | R | Pram (1.5 mg), CD/LD (25/100 mg) | 17 | ||
| p05 | 52 | M | 9 | R | CD/LD, Ropinirole | 62 | 42 |
| p06 | 70 | M | 5.5 | L | Rasagiline, Pram | 29 | 24 |
| p07 | 76 | M | 4 | L | Rasagiline (1 mg), CD/LD (50/200 mg) | 35 | 26 |
| p08 | 61 | M | L | Ropinirole (1 mg) | 15 | ||
| p09 | 60 | M | 1 | R | Ropinirole (1 mg) | 27 | 24 |
| p10 | 72 | F | 9 | L | Ropinirole | 13 | 13 |
| p11* | 54 | F | 6 | Pram (4.5 mg), CD/LD (25/100 mg) | 48 | 37 | |
| p12 | 64 | F | 8 | R | Pram (2 mg), Rasagiline (1 mg) | 27 | 16 |
| p13 | 67 | M | 1 | L | CD/LD (25/100 mg) | 23 | 20 |
| p14 | 66 | M | 3 | L | Rasagiline (1 mg), CD/LD (25/100 mg) | 53 | 53 |
| p15* | 69 | M | CD/LD (50/200 mg) | 52 | 43 | ||
| p16 | 52 | M | 6 | R | Ropinirole (8 mg) | 14 | 13 |
| p17 | 64 | M | 7 | L | CD/LD (25/100 mg), Aman | 28 | 19 |
| p18 | 64 | F | L | 19 | 14 | ||
| c01 | 68 | F | |||||
| c02 | 60 | F | |||||
| c03 | 69 | F | |||||
| c04 | 56 | M | |||||
| c05 | 69 | M | |||||
| c06 | 56 | M | |||||
| c07 | 70 | M | |||||
| c08 | 64 | M | |||||
| c09 | 83 | F | |||||
| c10 | 85 | M | |||||
| c11* | 53 | F | |||||
| c12 | 75 | M | |||||
| c13 | 71 | M | |||||
| c14 | 68 | M | |||||
| c15* | 53 | M | |||||
| c16 | 50 | M | |||||
| c17 | M |
M, male; F, female; R, right; L, left; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale; Pram, pramipexole; CD/LD, carbidopa/levodopa; Aman, amantadine.
*
Participants who were excluded from analysis due to major dental artifacts, large or repetitive head movements, or tremor-related (or exasperated) artifacts.